Collectively, these observations highlight a shift in the prostate tumor landscape following ADT, moving from AR-positive prostate cancer (PCA1) towards AR-negative/-low prostate cancer (PCA2 and PCA3). This evidence concerns the gene AR and prostate carcinoma.